Profile data is unavailable for this security.
About the company
GROUPE BERKEM SA is a France-based company. The Company is engaged in the chemical sector industry, and it manages four subsidiaries: Berkem, Adkalis, Lixol, Eurolyo. The first business activity, which is led by Berkem, is specialised in plant extraction. It targets the cosmetics and food industries, which itsupplies in natural active ingredients and plant extracts for use in formulation. The second division, represented by Eurolyo, offers its services in the freeze-drying of raw materials and finished products. The third, Adkalis, produces and distributes solutions that add value to building materials, wood in particular. These product lines are destined for more technical markets: wood processing markets (sawmills, carpenters, joiners, panel manufacturers, fitters, etc.) and the building industry (construction and maintenance-renovation). The fourth pole, Lixol, is specialized in the manufacturing of industrial resins for the paint, construction, timber treatment and ink industries.
- Revenue in EUR (TTM)51.94m
- Net income in EUR367.00k
- Incorporated2016
- Employees234.00
- LocationGroupe Berkem SA20 rue Jean DuvertBLANQUEFORT 33290FranceFRA
- Phone+33 564310660
- Websitehttps://www.groupeberkem.com/
More ▼
Mergers & acquisitions
| Acquired company | ALKEM:PAR since announced | Transaction value |
|---|---|---|
| Naturex Iberian Partners SL | -24.69% | -- |
Data delayed at least 15 minutes, as of May 07 2024 13:15 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valerio Therapeutics SA | 1.80m | -20.34m | 16.61m | 39.00 | -- | 1.12 | -- | 9.23 | -0.1694 | -0.1694 | 0.0149 | 0.0961 | 0.0459 | -- | 1.07 | -- | -51.92 | -34.19 | -67.72 | -40.59 | -161.28 | 7.09 | -1,130.22 | -586.99 | -- | -171.66 | 0.3607 | -- | 24.74 | -21.73 | -4.00 | -- | 32.39 | -- |
| Nfl Biosciences SAS | 0.00 | -3.48m | 17.30m | 3.00 | -- | 4.39 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
| Phaxiam Therapeutics SA | 1.33m | -23.49m | 17.77m | 51.00 | -- | 0.6938 | -- | 13.40 | -5.56 | -5.56 | 0.3139 | 4.22 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| SMAIO SA | 7.62m | 1.06m | 18.30m | 37.00 | 17.18 | 1.69 | 7.69 | 2.40 | 0.2038 | 0.2038 | 1.46 | 2.07 | 0.5624 | 0.1871 | 17.23 | 206,027.60 | 7.81 | -7.87 | 10.24 | -19.76 | 96.95 | 96.04 | 13.89 | -22.48 | 2.54 | 11.07 | 0.1991 | -- | 212.18 | 114.99 | -62.80 | -- | -- | -- |
| NicOx SA | 3.57m | -17.36m | 18.91m | 11.00 | -- | 0.4119 | -- | 5.29 | -0.3721 | -0.3721 | 0.0753 | 0.9128 | 0.0394 | -- | 1.83 | 324,909.10 | -19.13 | -19.22 | -21.35 | -20.78 | -- | -- | -485.70 | -370.14 | -- | -- | 0.3172 | -- | -54.78 | 7.25 | 36.57 | -- | -13.35 | -- |
| Advicenne SA | 2.37m | -10.39m | 21.20m | 25.00 | -- | -- | -- | 8.96 | -1.03 | -1.03 | 0.2342 | -1.40 | 0.1938 | 6.10 | 1.94 | 94,680.00 | -85.09 | -46.00 | -178.65 | -61.82 | -204.18 | -441.10 | -438.99 | -597.56 | 0.8356 | -6.22 | 4.33 | -- | -12.32 | 33.26 | 7.70 | -- | 26.86 | -- |
| Predilife SA | 317.79k | -4.22m | 23.44m | 19.00 | -- | -- | -- | 73.75 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 26.92m | 22.00 | -- | 6.67 | -- | 25.11 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Fermentalg SA | 4.06m | -14.15m | 28.11m | 57.00 | -- | 0.7209 | -- | 6.93 | -0.3233 | -0.3233 | 0.0932 | 0.7213 | 0.0753 | 0.533 | 3.35 | -- | -24.63 | -21.94 | -26.79 | -24.71 | 13.21 | 14.73 | -327.08 | -248.95 | 3.53 | -63.30 | 0.3323 | -- | -46.94 | 75.18 | -43.29 | -- | -11.01 | -- |
| Groupe Berkem SA | 51.94m | 367.00k | 29.85m | 234.00 | 28.33 | -- | 6.72 | 0.5747 | 0.0593 | 0.0593 | 2.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 55.32 | -- | 0.7065 | -- | -- | 1.39 | -- | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| Poxel SA | 1.55m | -44.24m | 30.05m | 30.00 | -- | -- | -- | 19.44 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
| Gensight Biologics SA | 1.27m | -26.22m | 30.96m | 16.00 | -- | -- | -- | 24.43 | -0.5427 | -0.5427 | 0.0269 | -0.4726 | 0.0723 | -- | 2,534.00 | 79,187.50 | -149.52 | -79.44 | -- | -144.54 | -- | -- | -2,069.53 | -1,036.27 | -- | -- | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Global Bioenergies SA | 3.25m | -8.66m | 33.45m | 46.00 | -- | 3.21 | -- | 10.29 | -0.4797 | -0.4797 | 0.1802 | 0.5743 | 0.1632 | 5.21 | 65.62 | 70,638.05 | -43.47 | -43.66 | -64.54 | -82.47 | -153.20 | -948.35 | -266.41 | -1,331.36 | 3.54 | -- | 0.2626 | -- | 365.83 | 36.25 | 27.78 | -- | -19.49 | -- |
| Abionyx Pharma SA | 4.75m | -3.90m | 34.47m | 63.00 | -- | 6.25 | -- | 7.26 | -0.1382 | -0.1382 | 0.1683 | 0.17 | 0.2968 | 28.49 | 4.18 | -- | -24.39 | -- | -38.01 | -- | 11.22 | -- | -82.19 | -- | 0.9785 | -3,882.00 | 0.4732 | -- | -- | -- | -- | -- | -- | -- |
| genOway SA | 18.63m | 1.59m | 39.60m | 124.00 | 23.54 | 2.32 | 9.87 | 2.13 | 0.1814 | 0.1814 | 2.12 | 1.84 | 0.5813 | 0.3881 | 2.50 | 142,180.80 | 4.98 | -0.5615 | 6.72 | -0.8058 | 97.61 | 93.72 | 8.56 | -1.12 | 2.10 | 17.42 | 0.3344 | -- | 21.64 | 11.57 | 341.09 | -16.63 | -18.02 | -- |
| Biosynex SA | 93.05m | -13.79m | 42.98m | 560.00 | -- | -- | -- | 0.4619 | -1.94 | -1.94 | -- | -- | -- | -- | -- | 248,141.30 | -- | 25.60 | -- | 33.90 | 25.22 | 51.82 | -13.15 | 20.26 | -- | -4.45 | -- | 14.72 | -48.61 | 45.12 | -84.99 | 118.26 | -- | -- |
Data as of May 07 2024. Currency figures normalised to Groupe Berkem SA's reporting currency: Euro EUR
21.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 30 Apr 2024 | 1.41m | 7.95% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Dec 2022 | 1.01m | 5.71% |
| Mirova SA (Investment Management)as of 29 Feb 2024 | 700.13k | 3.94% |
| Lupus alpha Asset Management AGas of 30 Jun 2023 | 309.60k | 1.74% |
| Amber Capital (UK) LLPas of 31 Aug 2022 | 100.99k | 0.57% |
| Cr�dit Mutuel Asset Management SAas of 30 Jun 2023 | 98.00k | 0.55% |
| HSBC Global Asset Management (France) SAas of 29 Feb 2024 | 97.36k | 0.55% |
| UBS LA MAISON de Gestionas of 30 Dec 2022 | 35.00k | 0.20% |
| Pure Capital SAas of 31 Dec 2023 | 23.71k | 0.13% |
| Intesa Sanpaolo Wealth Management SAas of 31 Dec 2022 | 12.50k | 0.07% |
More ▼
Data from 31 Aug 2022 - 30 Apr 2024Source: FactSet Research Systems Inc.
